Cagrilintide

Most satiety research focuses on GLP-1 receptors. Cagrilintide targets a different system entirely. It's a long-acting amylin receptor agonist — an acylated analog of human amylin (IAPP), the 37-amino-acid peptide co-secreted alongside insulin from pancreatic beta cells. The amylin receptor is a calcitonin receptor/RAMP complex, and its activation produces satiety through brainstem signaling rather than the hypothalamic GLP-1 circuits that dominate metabolic peptide research. Same behavioral outcome, completely different receptor system. CAS: 2171029-28-8. MW ~3,900 Da. Novo Nordisk added an acyl chain to extend the half-life to approximately one week — the same fatty acid attachment strategy used with semaglutide.

The CagriSema Combination

Cagrilintide is being developed alongside semaglutide as CagriSema — a fixed-ratio once-weekly dual research protocol targeting two independent satiety pathways simultaneously. Phase 2 COMBINE data showed enhanced metabolic endpoints versus either component alone, which is the expected result when two distinct biological targets are engaged rather than simply doubling the dose on one receptor. The additive effect is the point.

For satiety neuroscience: amylin signaling converges on the area postrema and nucleus of the solitary tract — different brainstem nuclei than GLP-1. The RAMP protein combinations that form amylin receptor subtypes (RAMP1, RAMP2, RAMP3 each produce pharmacologically distinct complexes) add specificity that pure GLP-1 research doesn't capture. This is one of the more mechanistically interesting compounds in the satiety space precisely because it accesses a pathway that's often overlooked.

Specifications

Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.

Quality: HPLC purity analysis, mass spec identity confirmation, endotoxin testing on every batch. COA ships with every order. EU-based QC under CERTALAB S.R.L.

For research purposes only. Not for human consumption.